7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,884.90

-146.50

-3.63%

77,270.21

+626.77

+0.82%

Crude Oil Dec 26

102.95

+0.95

+0.93%

US Private Equity

10,850.63

-82.20

-0.75%

Taiwan - Delayed Quote TWD

PharmaEssentia Corporation (6446.TW)

1,190.00 -50.00 (-4.03%)

At close: October 30 at 1:30:13 PM GMT+8

Loading Chart for 6446.TW

Chart Range Bar

Interval:

In partnership with ChartIQ

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core

From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer

FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings

PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera

PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera

PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics

PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics

Mobilize your Website

View Site in Mobile | Classic

Share by: